We are live on ! Find out more
VM

VHCP Management Portfolio holdings

AUM $93M
1-Year Est. Return 10.04%
This Fund
S&P 500
This Quarter Est. Return
+72.29%
1 Year Est. Return
-10.04%
3 Year Est. Return
+233.99%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$181M
AUM Growth
+$46.4M
Cap. Flow
-$666K
Cap. Flow %
-0.37%
Top 10 Hldgs %
86%
Holding
20
New
3
Increased
1
Reduced
4
Closed
2

Top Buys

Rank Stock Value
1
BCRX icon
BioCryst Pharmaceuticals
BCRX
+$5.92M
2
HRTX icon
Heron Therapeutics
HRTX
+$3.04M
3
ISEE
IVERIC bio, Inc. Common Stock
ISEE
+$1.49M

Top Sells

Rank Stock Value
1
NBIX icon
Neurocrine Biosciences
NBIX
+$9.53M
2
VNDA icon
Vanda Pharmaceuticals
VNDA
+$3.17M
3
STML
Stemline Therapeutics, Inc.
STML
+$1.19M
4
HPTX
HYPERION THERAPEUTICS INC COM STK (DE)
HPTX
+$937K
5
ALBO
Albireo Pharma Inc
ALBO
+$715K

Sector Composition

Rank Sector Weight
1 Healthcare 63.57%
2 Miscellaneous 36.43%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
DYAX
1
DELISTED
DYAX CORPORATION
DYAX
$28.5M 15.75%
4,156,508
– –
IRWD icon
2
Ironwood Pharmaceuticals
IRWD
$701M
$21.3M 11.77%
2,149,200
– –
KERX
3
DELISTED
Keryx Biopharmaceuticals Inc
KERX
$20.7M 11.42%
2,048,773
– –
ANAC
4
DELISTED
ANACOR PHARMACEUTICALS INC COM
ANAC
$17.1M 9.45%
1,610,856
– –
BCRX icon
5
BioCryst Pharmaceuticals
BCRX
$2.52B
$15.9M 8.77%
2,180,656
+1,167,214
+115% +$5.92M
GWPH
6
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
$14.5M 8.02%
837,800
– –
NBIX icon
7
Neurocrine Biosciences
NBIX
$15.8B
$14.4M 7.95%
1,271,303
-693,370
-35% -$9.53M
TSRO
8
DELISTED
TESARO, Inc.
TSRO
$10.1M 5.59%
261,130
– –
CHTP
9
DELISTED
CHELSEA THERAPEUTICS INT'L LTD
CHTP
$7.53M 4.16%
2,516,870
– –
HPTX
10
DELISTED
HYPERION THERAPEUTICS INC COM STK (DE)
HPTX
$5.68M 3.14%
217,571
-37,429
-15% -$937K
VNDA icon
11
Vanda Pharmaceuticals
VNDA
$329M
$5.38M 2.97%
491,075
-296,384
-38% -$3.17M
ALBO
12
DELISTED
Albireo Pharma Inc
ALBO
$4.04M 2.23%
42,720
-5,494
-11% -$715K
MTEM
13
DELISTED
Molecular Templates, Inc.
MTEM
$3.18M 1.76%
4,145
– –
HRTX icon
14
Heron Therapeutics
HRTX
$63M
$3.04M 1.68%
+453,385
New +$3.04M
ALXA
15
DELISTED
Alexza Pharmaceuticals Inc
ALXA
$2.05M 1.13%
399,999
– –
ISEE
16
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$1.56M 0.86%
+52,500
New +$1.49M
ONCT
17
DELISTED
Oncternal Therapeutics, Inc. Common Stock
ONCT
$1.01M 0.56%
357
– –
STML
18
DELISTED
Stemline Therapeutics, Inc.
STML
– –
-50,000
Closed -$1.19M
ANTH
19
DELISTED
Anthera Pharmaceuticals, Inc.
ANTH
– –
-22,463
Closed -$666K

Similar funds

QGI
Quadrangle GP Investors New York $93.6M AUM 10.64% 1-Year Est. Return
KC
Kanha Capital New York $89.9M AUM
RSCM
Rail-Splitter Capital Management Chicago, Illinois $89.4M AUM 15.13% 1-Year Est. Return
ZC
Zelman Capital Beachwood, Ohio $81.9M AUM 22.32% 1-Year Est. Return
TF
Trutina Financial Bellevue, Washington $76.7M AUM 19.34% 1-Year Est. Return
SAM
Sunnymeath Asset Management Red Bank, New Jersey $71.2M AUM 26.57% 1-Year Est. Return
NA
NS Advisors Westport, Connecticut $71M AUM 25.21% 1-Year Est. Return
NCIM
New Century Investment Management Southfield, Michigan $70.5M AUM 23.2% 1-Year Est. Return

VHCP Management's Q3 2013 Portfolio in Review

As of Q3 2013, VHCP Management held 20 positions worth $181M, up 34% from $135M the previous quarter. Its ten largest holdings account for 86% of the portfolio.

VHCP Management's Q3 2013 filing shows 3 new, 1 increased, 4 reduced and 2 closed positions. Its largest new stake was Heron Therapeutics: 453,385 shares worth $3.04M. The largest sale was Neurocrine Biosciences, an estimated $9.53M.

By sector, the portfolio is most concentrated in Healthcare at 64% of assets, down from 73% a quarter earlier, followed by Miscellaneous.

  • VHCP Management's largest Q3 2013 buy was Heron Therapeutics: 453,385 shares worth $3.04M.
  • VHCP Management added most to BioCryst Pharmaceuticals in Q3 2013, an estimated $5.92M increase.
  • VHCP Management's biggest Q3 2013 reduction was Neurocrine Biosciences, cutting an estimated $9.53M.
  • VHCP Management fully exited Stemline Therapeutics, Inc. in Q3 2013, selling an estimated $1.19M.
  • VHCP Management's ten largest holdings make up 86% of its $181M portfolio in Q3 2013.
  • VHCP Management opened 3 new positions and closed 2 in Q3 2013.
  • VHCP Management's portfolio value rose 34% quarter-over-quarter to $181M.

Based on VHCP Management's 13F filing for Q3 2013, filed 15 Nov 2013.